Pfizer Gets First Approval Of Arena’s Etrasimod, In Ulcerative Colitis

Branded as Velsipity, the S1P modulator will compete directly against classmate Zeposia in UC and faces a crowded field of anti-TNFs and other types of therapy. Pfizer paid $6.7bn for Arena in 2021.